Phillips, Roger - Huddersfield University

个人简介

Following a BSc in Marine Biology and Biochemistry (Joint Honours) from University College of North Wales, Bangor, Roger specialised in Cancer Pharmacology gaining his PhD in 1988 from the University of Bradford (under Profs John Double and Mike Bibby). After an initial postdoctoral position in Bradford, he moved to the School of Pharmacy, University of Southern California, Los Angeles to work with Dr Neil Gibson in 1991. He returned to Bradford in 1993 and secured academic appointments as lecturer (1996 to 2001), Senior Lecturer (2001 to 2003) and Reader (2003 to 1014) in Cancer Pharmacology. In July 2014, Roger was appointed as Professor of Cancer Pharmacology at the University of Huddersfield. He was also appointed as Director of Research in the School of Applied Sciences in August 2015. His research focuses on the preclinical and early clinical evaluation of novel anti-cancer drugs with a specific interest in the tumour microenvironment as a target for drug development. His research has had clinical impact through the development of EO9 as a therapeutic drug for the treatment of superficial bladder cancer. He has published extensively in internationally recognised journals, has successfully supervised over 20 PhD students and continues to present his work at national and international conferences. He is a committee member of the European Organisation for the Research and Treatment of Cancer (EORTC) Drug Development Committee and the Pharmacology and Molecular Mechanism Group. He is also an editorial board member for the British Journal of Pharmacology.

研究领域

Roger has over 28 years experience in the preclinical and early clinical development of novel anti-cancer drugs publishing over 100 in peer-reviewed journals. He has expertise in all areas of preclinical drug development ranging from cell free to in vivo pharmacokinetic and pharmacodynamics studies including participation in clinical trials. Of the compounds he has worked on, several have progressed to clinical trial (Flavone Acetic Acid, AQ4N, RH1, Phortress) but his major achievement is providing the rationale and pre-clinical evidence to progress EO9 (a bioreductive pro-drug targeting the tumour microenvironment) into clinical trial against superficial bladder cancer. Together with Urologists at Bradford Royal Infirmary, he designed and oversaw the conduct of the clinical trial that demonstrated that EO9 was clinically active. EO9 is currently undergoing phase III clinical evaluation in North America and Europe. He has worked closely with a number of medicinal chemists to provide pharmacological information on the mechanism of action of novel compounds and has the experience and expertise to progress compounds through preclinical testing to early clinical trial. His current research interests include: Preclinical development of novel anti-cancer drugs Phenotype based screening Development of experimental models that reflect the complexity of tumour biology The hypoxic tumour microenvironment as a target for drug development Drug delivery to hypoxic regions of solid tumours

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Adhikari, S., Palepu, N., Sutradhar, D., Shepherd, S., Phillips, R., Kaminsky, W., Chandra, A. and Kollipara, M. (2016) ‘Neutral and cationic half-sandwich arene ruthenium, Cp*Rh and Cp*Ir oximato and oxime complexes: Synthesis, structural, DFT and biological studies’ Journal of Organometallic Chemistry . ISSN 0022-328X Adhikari, S., Sutradhar, D., Shepherd, S., Phillips, R., Chandra, A. and Rao, K. (2016) ‘Synthesis, structural, DFT calculations and biological studies of rhodium and iridium complexes containing azine Schiff-base ligands’ Polyhedron . ISSN 0277-5387 Phillips, R (2016) ‘Targeting the hypoxic fraction of tumours using hypoxia activated prodrugs’ Cancer Chemotherapy and Pharmacology , 77 (3), pp. 441-457. ISSN 0344-5704 Lucas, S., Lord, R., Basri, A., Allison, S., Phillips, R., Blacker, A. and McGowan, P. (2016) ‘Increasing anti-cancer activity with longer tether lengths of group 9 Cp* complexes’ Dalton Transactions (16). ISSN 1477-9226 Javid, F., Phillips, R., Afshinjavid, S., Verde, R. and Ligresti, A. (2016) ‘Cannabinoid pharmacology in cancer research: A new hope for cancer patients?’ European Journal of Pharmacology . ISSN 0014-2999 Kaner, R., Allison, S., Faulkner, A., Phillips, R., Roper, D., Shepherd, S., Simpson, D., Waterfield, N. and Scott, P. (2015) ‘Anticancer metallohelices: nanomolar potency and high selectivity’ Chemical Science . ISSN 2041-6520 Lord, R., Hebden, A., Pask, C., Henderson, I., Allison, S., Shepherd, S., Phillips, R. and McGowan, P. (2015) ‘Hypoxia Sensitive Metal ?-Ketoiminate Complexes Showing Induced Single Strand DNA Breaks and Cancer Cell Death by Apoptosis’ Journal of Medicinal Chemistry , 58 (12), pp. 4940-4953. ISSN 0022-2623 Mohamed, H., Lake, B., Laing, T., Phillips, R. and Willans, C. (2015) ‘Synthesis and anticancer activity of silver(I)– N-heterocyclic carbene complexes derived from the natural xanthine products caffeine, theophylline and theobromine’ Dalton Transactions , 44 (16), pp. 7563-7569. ISSN 1477-9226 Rodríguez-Bárzano, A., Lord, R., Basri, A., Phillips, R., Blacker, A. and McGowan, P. (2015) ‘Synthesis and anticancer activity evaluation of ?5-C5(CH3)4R ruthenium complexes bearing chelating diphosphine ligands’ Dalton Transactions , 44 (7), pp. 3265-3270. ISSN 1477-9226 Ramirez, Y., Mladek, A., Phillips, R., Gynther, M., Rautio, J., Ross, A., Wheelhouse, R. and Sakaria, J. (2015) ‘Evaluation of Novel Imidazotetrazine Analogues Designed to Overcome Temozolomide Resistance and Glioblastoma Regrowth’ Molecular Cancer Therapeutics , 14, pp. 111-119. ISSN 1535-7163 Wong, C., Periasamy, N., Sagineedu, S., Sidik, S., Sumon, S., Loadman, P., Phillips, R., Lajis, N. and Stanslas, J. (2014) ‘In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog’ Investigational new drugs , 32 (5), pp. 806-814. ISSN 0167-6997 Kalidasan, M., Forbes, S., Mozharivskyj, Y., Ahmadi, M., Ahmadihosseini, Z., Phillips, R. and Kollipara, M. (2014) ‘Mononuclear half-sandwich cyclic-p-perimeter platinum group metal complexes having bithiazole ligands: Synthesis, molecular and anti- cancer studies’ Inorganica Chimica Acta , 421, pp. 349-358. ISSN 0020-1693 Wong, C., Sagineedu, S., Sumon, S., Sidik, S., Phillips, R., Lajis, N. and Stanslas, J. (2014) ‘NCI in vitro and in silico anticancer screen, cell cycle pertubation and apoptosis-inducing potential of new acylated, benzylidene and isopropylidene derivatives of andrographolide’ Environmental Toxicology and Pharmacology , 38 (2), pp. 489-501. Faulkner, A., Kaner, R., Abdallah, Q., Clarkson, G., Fox, D., Gurnani, P., Howson, S., Phillips, R., Roper, D., Simpson, D. and Scott, P. (2014) ‘Asymmetric triplex metallohelices with high and selective activity against cancer cells’ Nature Chemistry , 6 (9), pp. 797-803. ISSN 17554330 Lord, R., Mannion, J., Hebden, A., Nako, A., Crossley, B., McMullon, M., Janeway, F., Phillips, R. and McGowan, P. (2014) ‘Mechanistic and Cytotoxicity Studies of Group IV b-Diketonate Complexes’ ChemMedChem Communications , 9 (6), pp. 1136-1139. ISSN 1860-7179 Allison, S., Knight, J., Granchi, C., Rani, R., Minutolo, F., Milner, J. and Phillips, R. (2014) ‘Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways’ Oncogenesis , 3 (e102), pp. 1-11. ISSN 2157-9024 Groh, C., Hubbard, M., Jones, P., Loadman, P., Periasamy, R., Sleeman, B., Smye, S., Twelves, C. and Phillips, R. (2014) ‘Mathematical and computational models of drug transport in tumours’ Interface: Journal of the Royal Society , 11 (94), p. 1173. ISSN 1742-5662 Almodares, Z., Lucas, S., Crossley, B., Basri, A., Pask, C., Hebden, A., Phillips, R. and McGowan, P. (2014) ‘Rhodium, Iridium, and Ruthenium Half-Sandwich Picolinamide Complexes as Anticancer Agents’ Inorganic Chemistry , 53 (2), pp. 727-736. ISSN 0020-1669 Ahmadi, M., Ahmadihosseini, Z., Allison, S., Begum, S., Rockley, K., Sadiq, M., Chintamaneni, S., Lokwani, R., Hughes, N. and Phillips, R. (2014) ‘Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors’ British Journal of Pharmacology , 171 (1), pp. 224-236. ISSN 0007-1188 Brabec, V., Howson, S., Kaner, R., Lord, R., Malina, J., Phillips, R., Abdallah, Q., McGowan, P., Rodger, A. and Scott, P. (2013) ‘Metallohelices with activity against cisplatin-resistant cancer cells; does the mechanism involve DNA binding?’ Chemical Science , 4 (12), pp. 4407-4416. ISSN 2041-6520